货号:A445850 同义名: TKI-258 lactate;CHIR-258 lactate
Dovitinib lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) with an IC50 of 5 nM.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | c-Kit ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tyrphostin AG1296 |
+
c-Kit (Swiss 3T3), IC50: 1.8 μM |
PDGFR | 99%+ | ||||||||||||||||
Masitinib |
+
Kit, IC50: 200 nM |
99%+ | |||||||||||||||||
Motesanib Diphosphate |
+++
Kit, IC50: 8 nM |
98% | |||||||||||||||||
Ki8751 |
++
c-Kit, IC50: 40 nM |
98+% | |||||||||||||||||
Tivozanib |
++
c-Kit, IC50: 78 nM |
99%+ | |||||||||||||||||
Pazopanib |
+
c-Kit, IC50: 140 nM |
99% | |||||||||||||||||
Sitravatinib |
+++
Kit, IC50: 6 nM |
99%+ | |||||||||||||||||
Pexidartinib |
+++
Kit, IC50: 10 nM |
99%+ | |||||||||||||||||
Lactate |
++++
c-Kit, IC50: 2 nM |
FLT3 | 85% | ||||||||||||||||
Amuvatinib |
+++
c-Kit (D816H), IC50: 10 nM |
99%+ | |||||||||||||||||
Imatinib Mesylate |
+
c-Kit, IC50: 100 nM |
PDGFR | 99% | ||||||||||||||||
AZD2932 |
+++
c-Kit, IC50: 9 nM |
98% | |||||||||||||||||
Axitinib |
++++
Kit, IC50: 1.7 nM |
98% | |||||||||||||||||
Dovitinib |
++++
c-Kit, IC50: 2 nM |
FLT3 | 99%+ | ||||||||||||||||
Sunitinib | ✔ | FLT3 | 98% | ||||||||||||||||
OSI-930 |
+
Kit, IC50: 80 nM |
99%+ | |||||||||||||||||
Telatinib |
++++
c-Kit, IC50: 1 nM |
99%+ | |||||||||||||||||
Dasatinib monohydrate |
++
c-Kit (D816V), IC50: 37 nM c-Kit (wt), IC50: 79 nM |
Src | 98% | ||||||||||||||||
Dasatinib |
++
c-Kit (D816V), IC50: 37 nM c-Kit (wt), IC50: 79 nM |
Src | 98% | ||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
描述 | Fibroblast growth factors (FGFs) and FGF receptors (FGFRs) signaling network play essential roles to promote angiogenesis and tumor growth by binding to tyrosine kinase. Dovitinib (TKI258) is a small-molecule tyrosine kinase inhibitor targeting multiple RTKs, such as FGFRs. Dovitinib decreased the cell numbers in a dose-dependent manner in HCC1937 cells (IC50 = 13.8 μM), MCF-7 cells (IC50 = 12.7 μM), MDA-MB-231 cells (IC50 = 11.9 μM), MDA-MB-453 cells (IC50 = 9.7 μM), MDA-MB-468 cells (IC50 = 10.1 μM), and SK-BR-3 cells (IC50 = 11.7 μM). Dovitinib (0, 10, 15 μM; 24 h) induced the autophagy of various breast cancer cells through inhibiting STAT3/Mcl-1 axis in a dose-dependent manner. Treatment with 15 μM dovitinib induced about 15%, 40%, 25%, and 17% cell apoptosis at 24 h for MCF-7, MDA-MB-231, MDA-MB-468, and SK-BR-3 cells, respectively[3]. In mice bearing subcutaneous AN3CA, MFE296, SNGM, or HEC1A tumor xenografts, dovitinib (daily oral doses of 30 or 50 mg/kg) significantly delayed the growth of FGFR2-mutated endometrial cancer xenograft tumors. Of note, complete tumor regressions were observed in the majority of tumors at a dovitinib dose of 50 mg/kg in the SNGM xenograft model[4]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT01678105 | Recurrent Adenoid Cystic Carci... 展开 >>noma of the Salivary Glands Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Salivary Gland Cancers ACC 收起 << | Phase 2 | Completed | - | Canada, Ontario ... 展开 >> Tom Baker Cancer Centre Calgary, Ontario, Canada, T2N 4N2 Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 London Health Sciences Centre London, Ontario, Canada, N6A 4L6 Ottawa Hospital Regional Cancer Centre Ottawa, Ontario, Canada, K1H 8L6 收起 << |
NCT01223027 | Metastatic Renal Cell Carcinom... 展开 >>a 收起 << | Phase 3 | Completed | - | - |
NCT01496534 | Solid Tumors ... 展开 >>Bladder Cancer 收起 << | Phase 1 | Terminated(toxicity of combina... 展开 >>tion of medications) 收起 << | - | United States, New York ... 展开 >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 收起 << |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.07mL 0.41mL 0.21mL |
10.36mL 2.07mL 1.04mL |
20.73mL 4.15mL 2.07mL |
CAS号 | 692737-80-7 |
分子式 | C24H27FN6O4 |
分子量 | 482.507 |
别名 | TKI-258 lactate;CHIR-258 lactate |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Inert atmosphere,Room temperature |
溶解度 |
DMSO: 25 mg/mL(51.81 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |